SEMINOMA
Clinical trials for SEMINOMA explained in plain language.
Never miss a new study
Get alerted when new SEMINOMA trials appear
Sign up with your email to follow new studies for SEMINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Testicular cancer trial: could a stronger chemo course slash relapse risk?
Disease control OngoingThis phase 3 trial tests whether one round of BEP chemotherapy works better than one round of carboplatin to stop stage I seminoma testicular cancer from coming back. About 348 men with high-risk features (tumor over 4 cm or invasion of the rete testis) are being studied. The goa…
Matched conditions: SEMINOMA
Phase: PHASE3 • Sponsor: St. Olavs Hospital • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC
-
New hope for incurable testicular and ovarian cancers?
Disease control OngoingThis study tests the drug cabozantinib in 50 adults with germ cell tumors (like testicular or ovarian cancer) that have not responded to standard chemotherapy. The goal is to see if the drug can shrink tumors or stop them from growing for at least 3 months. Participants will take…
Matched conditions: SEMINOMA
Phase: PHASE2 • Sponsor: Jennifer King • Aim: Disease control
Last updated Jun 22, 2026 12:09 UTC
-
Can less be more? new trial aims to reduce side effects in testicular cancer treatment
Disease control OngoingThis phase 2 trial tests whether reducing the intensity of chemotherapy and radiation can safely treat stage IIA/B seminoma, a type of testicular cancer. About 135 patients will receive either carboplatin alone or a combination of cisplatin and etoposide, along with lower-dose ra…
Matched conditions: SEMINOMA
Phase: PHASE2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 22, 2026 12:00 UTC
-
Immunotherapy duo takes on rare cancers in Largest-Ever trial
Disease control OngoingThis study tested a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 different rare tumor types. The goal was to see if these drugs could shrink tumors and help control the cancer. The trial is no longer recruiting, and results are bein…
Matched conditions: SEMINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 18, 2026 11:46 UTC
-
New drug duo targets stubborn germ cell cancers
Disease control OngoingThis study tests two immunotherapy drugs, durvalumab and tremelimumab, in people whose germ cell tumors have come back or not responded to standard treatment. The goal is to see if this combination can shrink tumors or control the disease. About 30 adults with measurable tumors w…
Matched conditions: SEMINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Blood marker may predict cancer return in testicular tumor patients
Knowledge-focused OngoingThis study is testing whether a blood marker called miRNA 371 can predict if germ cell tumors (a type of cancer) will return after treatment. Researchers will collect blood samples from 956 newly diagnosed patients and track who has a relapse. The goal is to see if this marker ca…
Matched conditions: SEMINOMA
Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated Jun 18, 2026 11:50 UTC